Zura Bio (NASDAQ:ZURA) Posts Earnings Results, Beats Expectations By $0.09 EPS

Zura Bio (NASDAQ:ZURA) posted its earnings results on Tuesday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09, Zacks reports. The firm had revenue of $0.00 million for the quarter.

Zura Bio Stock Performance

Shares of NASDAQ ZURA traded up $0.04 during midday trading on Thursday, hitting $1.38. The stock had a trading volume of 41,895 shares, compared to its average volume of 351,005. Zura Bio has a 1-year low of $1.07 and a 1-year high of $6.35. The company has a fifty day moving average price of $1.48 and a 200 day moving average price of $2.76.

Institutional Investors Weigh In On Zura Bio

An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE increased its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,222 shares of the company’s stock after purchasing an additional 9,966 shares during the period. Bank of America Corp DE owned 0.06% of Zura Bio worth $103,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Wall Street Analysts Forecast Growth

ZURA has been the topic of a number of analyst reports. Guggenheim restated a “buy” rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday. Chardan Capital cut their price target on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. Oppenheimer reaffirmed an “outperform” rating and set a $19.00 price target (down from $20.00) on shares of Zura Bio in a report on Wednesday. HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.00.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.